Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US and Canadian approval for Polish isotope reactor

This article was originally published in Clinica

Executive Summary

The US FDA and Health Canada have approved the Maria Research reactor in Poland to produce the medical isotope molybdenum-99 (Mo-99). The decision follows an agreement in February between Poland's institute of atomic energy and Covidien, which will use the Mo-99 to manufacture technetium-99m, the most widely-used radioisotope for nuclear medicine imaging (www.clinica.co.uk, 24 February 2010). The move could go some way towards easing the isotope crisis that started when Canada's Chalk River facility shut down for maintenance last May, and was exacerbated when the Petten reactor in the Netherlands was also closed two months later. The Canadian reactor is due to re-open in April (www.clinica.co.uk, 11 February 2010).

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT058891

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel